Tocilizumab in severe and refractory non-infectious uveitis

Clinical and Experimental Rheumatology

Volumn 32, Issue , 2014, Pages S75-S79

  Papo, Matthias ^a,b   Bielefeld, Philip ^c   Vallet, Hélène ^a,b   Seve, Pascal ^d   Wechsler, Bertrand ^a,b   Cacoub, Patrice ^a,b   Le Hoang, Phuc ^a   Papo, Thomas ^e   Bodaghi, Bahram ^a   Saadoun, David ^a,b  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c DIJON UNIVERSITY HOSPITAL   (France)

^d CROIX ROUSSE HOSPITAL   (France)

^e BICHAT HOSPITAL   (France)

Author keywords

Beh et's disease; Tocilizumab; Uveitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TOCILIZUMAB; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BEHCET DISEASE; BIRDSHOT CHORIORETINOPATHY; BRONCHITIS; CHORIORETINOPATHY; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; IDIOPATHIC BILATERAL PANUVEITIS; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; RELAPSE; THROMBOCYTOPENIA; TREATMENT RESPONSE; UVEA DISEASE; UVEITIS; VISUAL ACUITY; YOUNG ADULT; BEHCET SYNDROME; CLINICAL TRIAL; COMPLICATION; DRUG RESISTANCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; BEHCET SYNDROME; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UVEITIS;

EID: 84907560583     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. JABS DA, ROSENBAUM JT: Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2001; 131: 679.
2. CAORSI R, FEDERICI S, GATTORNO M: Biologic drugs in autoinflammatory syndromes. Autoimmun Rev 2012; 12: 81-6.
3. SAADOUN D, BODAGHI B, BIENVENU B et al.: Biotherapies in inflammatory ocular disorders:Interferons, immunoglobulins, monoclonal antibodies. Autoimmun Rev 2013; 12: 774-83.
4. KALY L, ROSNER I: Tocilizumab-a novel therapy for non-organ-specific autoimmune diseases. Best Pract Res Clin Rheumatol 2012; 26: 157-65.
5. PAZZOLA G, PADOVANO I, BOIARDI L et al.: Tocilizumab in glucocorticoid-naïve large-vessel vasculitis. Clin Exp Rheumatol 2013; 31 (Suppl. 75): S59-61.
6. BENUCCI M, MANFREDI M, SAVIOLA G, SARZI-PUTTINI P, ATZENI F: Changes in atherosclerosis markers during tocilizumab treatment in rheumatoid arthritis: preliminary results. Clin Exp Rheumatol 2013; 31: 322-3.
7. KIMURA A, NAKA T, KISHIMOTO T: IL-6-dependent and-independent pathways in the development of interleukin 17-producing T helper cells. Proc Natl Acad Sci USA 2007; 104: 12099-104.
8. MIHARA M, OHSUGI Y, KISHIMOTO T: Evidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by anti-interleukine-6 receptor antibody. Biofactors 2009; 35: 47-51.
9. YOSHIMURA T, SONODA KH, OHGURO N et al.: Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis, Rheumatology (Oxford) 2009; 48: 347-54.
10. HOHKI S, OHGURO N, HARUTA H et al.: Blockade of interleukin 6 signaling suppresses experimental auto-immune uveoretinitis by the inhibition of inflammatory Th17 responses, Exp Eye Res 2010; 91: 162-70.
11. HARUTA H, OHGURO N, FUJIMOTO M et al.: Blockade of Interleukin-6 signaling supresses not only Th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting Regulatory T Cells in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 2011; 52: 3264-71.
12. MUSELIER A, BIELEFELD P, BIDOT S, VINIT J, BESANCENOT JF, BRON A: Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm 2011; 19: 382-3.
13. HIRANO T, OHGURO N, HOHKI S et al.: A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol 2012; 22: 298-302.
14. YOSHIMURA T, SONODA KH, OHGURO N et al.: Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology (Oxford). 2009; 48: 347-54.
15. ADáN A, MESQUIDA M, LLORENç V et al.: Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol 2013; 251: 2627-32.
16. TAPPEINER C, HEINZ C, GANSER G, HEILIGENHAUS A: Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol 2012; 39: 1294-5.
17. JONES G, SEBBA A, GU J et al.: Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010; 69: 88-96.